Your Thyroid Antibodies Are High. Here's the Genetic Reason.

TPO is an enzyme your thyroid uses to synthesize thyroid hormones. It’s essential for converting iodine into T3 and T4. Your immune system should never attack it, but in Hashimoto’s thyroiditis, it does. TPO becomes the bullseye. When TPO variants are present, your thyroid becomes more recognizable as a target to your immune system, or your immune system becomes more likely to tolerate an attack once it starts.

The TPO variants associated with Hashimoto’s (rs11675434 and others) are carried by roughly 20-30% of the population. Here’s the key: having the variant doesn’t guarantee antibodies will develop, but it dramatically increases the probability that once they appear, they’ll be directed at TPO specifically, and that they’ll persist. This is why some people with TPO antibodies have a slow decline, while others remain stable for years.

If you have TPO variants and elevated TPO antibodies, you’re experiencing a direct immune attack on your thyroid’s hormone-making machinery. That’s different from Graves’ disease, where antibodies stimulate the thyroid. With TPO, the antibodies are destroying function. The longer the attack continues without intervention, the more thyroid tissue is lost.

TSHR is the receptor on your thyroid cell surface that responds to TSH, the signal from your pituitary telling your thyroid to produce more hormone. It’s also where your immune system can go wrong. In Graves’ disease, antibodies stimulate TSHR, causing thyroid hormone overproduction. But TSHR variants also affect how your immune system learns to tolerate your thyroid, and whether it mounts a defense against it. TSHR controls the sensitivity and reactivity of your thyroid cells to immune signals.

TSHR variants are present in roughly 10-20% of the population. These variants affect TSH receptor sensitivity and are associated with autoimmune thyroid disease risk, including both Hashimoto’s and Graves’ disease. The variants that increase autoimmunity typically reduce immune tolerance, meaning your immune system is more likely to perceive your thyroid as foreign and mount an attack.

If you have TSHR variants and elevated thyroid antibodies, your immune system is not just attacking TPO; it’s also targeting the receptor that controls your thyroid’s fundamental function. This is why some people with antibodies also experience TSH fluctuations and variable symptom severity. The immune attack isn’t consistent; it waxes and wanes.

DIO2 is the enzyme responsible for converting T4 (the storage form of thyroid hormone) into T3 (the active form your cells actually use). Your thyroid produces mostly T4. Your body has to convert it to T3 in the tissues that need it. DIO2 does much of that work, especially in the brain, muscle, and immune tissue. If DIO2 is working poorly, you have plenty of T4 circulating but not enough active T3 where it matters most.

The DIO2 Thr92Ala variant (rs225014) is carried by roughly 12-15% of the population in the Ala/Ala genotype. People with this variant have significantly impaired T4-to-T3 conversion, meaning they may have ‘normal’ TSH and T4 on their bloodwork but feel persistently hypothyroid because their tissues are starved of active T3. This is particularly important when you have elevated antibodies, because reduced T3 in immune tissue can worsen autoimmune responses.

If you have DIO2 variants and elevated thyroid antibodies, you’re likely dealing with a double hit: your immune system is attacking your thyroid, and the thyroid hormone you do produce isn’t being converted efficiently. You’ll feel more exhausted, more brain fog, more depression than your TSH suggests you should. Standard levothyroxine alone often doesn’t help, because the problem isn’t T4 production; it’s T4 utilization.

MTHFR regulates methylation, the process your cells use to copy DNA, regulate genes, and support nearly every cellular function including immune tolerance. Impaired methylation doesn’t just slow your metabolism; it specifically impairs the ability of your immune system to distinguish self from non-self, and it reduces the function of selenoproteins, the enzymes that protect your thyroid from oxidative damage. Selenium-dependent enzymes are foundational to thyroid health, and methylation is required to activate them.

The MTHFR C677T variant is carried by roughly 40% of people with European ancestry. This variant reduces methylation efficiency by 35-40% in heterozygotes and up to 70% in homozygotes, which impairs both immune tolerance and the activity of thyroid-protective selenoproteins. People with C677T variants and elevated thyroid antibodies often have particularly aggressive autoimmune responses because their immune regulation is compromised at the methylation level.

If you have MTHFR variants and elevated thyroid antibodies, standard B vitamin supplementation won’t help; you need the methylated forms. Your immune system isn’t just attacking your thyroid; it’s struggling to recognize your thyroid as self because your methylation is impaired. This is why some people with antibodies also develop other autoimmune conditions: poor methylation breaks immune tolerance across the board.

VDR is the receptor that allows your cells to use vitamin D. Vitamin D isn’t just for bone health; it’s a master switch for immune tolerance. When your VDR is working properly, vitamin D signals your immune system to create T-regulatory cells, which suppress autoimmune attacks. When VDR variants are present, vitamin D signaling is impaired, and your immune system loses the brake that would normally prevent it from attacking your own tissues.

VDR variants (FokI, BsmI, ApaI, TaqI polymorphisms) are present in roughly 30-50% of the population depending on ancestry and specific SNP. These variants reduce vitamin D receptor function, which means that even with adequate vitamin D levels, your immune system isn’t receiving the full “stand down” signal that would normally suppress thyroid-attacking antibodies. You can take vitamin D supplements and still have hyperactive autoimmunity because your cells can’t respond to it properly.

If you have VDR variants and elevated thyroid antibodies, your immune system is not getting the vitamin D signal to stop attacking. This is particularly important because VDR variants are associated with both higher thyroid antibody titers and faster progression to hypothyroidism. Your immune tolerance is genetically weakened, which means you need higher vitamin D levels and potentially other immune-modulating interventions to achieve the same degree of tolerance as someone with normal VDR function.

HLA-DQ2 is a gene that codes for part of your immune system’s antigen presentation machinery. It’s the complex on immune cells that displays pieces of proteins to other immune cells, teaching the immune system what to attack and what to tolerate. HLA-DQ2 has a particular “preference” for certain protein fragments. If your thyroid’s TPO or thyroglobulin happen to present fragments that HLA-DQ2 recognizes easily, your immune system is more likely to mount a response against them.

HLA-DQ2 is present in roughly 20-30% of people of European descent, and far more commonly in people of Mediterranean, Middle Eastern, and North African ancestry. People carrying HLA-DQ2 have a significantly increased risk of autoimmune thyroid disease because their immune system is genetically “primed” to recognize certain thyroid antigens as threats. Having the gene doesn’t guarantee antibodies will develop, but it determines whether your immune system can recognize thyroid targets in the first place.

If you have HLA-DQ2 and elevated thyroid antibodies, your immune attack is not accidental; your immune system is genetically wired to recognize your thyroid’s proteins as dangerous. This is why some families have high rates of Hashimoto’s; they share HLA-DQ2. It’s also why standard anti-inflammatory approaches sometimes don’t work: you’re not just dealing with excessive inflammation; you’re dealing with a specific immune targeting pattern that your genes have encoded.